OptiNose Current Deferred Revenue from 2010 to 2024

OPTN Stock  USD 0.54  0.04  8.00%   
OptiNose Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to drop to about 141.9 K. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
184 K
Current Value
141.9 K
Quarterly Volatility
64.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check OptiNose financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OptiNose's main balance sheet or income statement drivers, such as Interest Income of 2.7 M, Depreciation And Amortization of 611.7 K or Interest Expense of 10.9 M, as well as many indicators such as Price To Sales Ratio of 1.93, Dividend Yield of 0.0461 or Days Sales Outstanding of 97.33. OptiNose financial statements analysis is a perfect complement when working with OptiNose Valuation or Volatility modules.
  
Check out the analysis of OptiNose Correlation against competitors.
To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.

Latest OptiNose's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of OptiNose over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. OptiNose's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OptiNose's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

OptiNose Current Deferred Revenue Regression Statistics

Arithmetic Mean116,260
Geometric Mean94,815
Coefficient Of Variation55.61
Mean Deviation60,208
Median160,000
Standard Deviation64,655
Sample Variance4.2B
Range145K
R-Value0.79
Mean Square Error1.7B
R-Squared0.63
Significance0.0004
Slope11,444
Total Sum of Squares58.5B

OptiNose Current Deferred Revenue History

2024141.9 K
2023184 K
2018160 K
2016186 K

About OptiNose Financial Statements

OptiNose investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how OptiNose Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue184 K141.9 K

Pair Trading with OptiNose

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OptiNose position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OptiNose will appreciate offsetting losses from the drop in the long position's value.

Moving together with OptiNose Stock

  0.71VRAX Virax Biolabs GroupPairCorr

Moving against OptiNose Stock

  0.81ETON Eton Pharmaceuticals Downward RallyPairCorr
  0.7VRNA Verona Pharma PLCPairCorr
  0.61EWTX Edgewise TherapeuticsPairCorr
  0.49ELDN Eledon PharmaceuticalsPairCorr
  0.31DSGN Design TherapeuticsPairCorr
The ability to find closely correlated positions to OptiNose could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OptiNose when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OptiNose - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OptiNose to buy it.
The correlation of OptiNose is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OptiNose moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OptiNose moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OptiNose can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether OptiNose offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OptiNose's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Optinose Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Optinose Stock:
Check out the analysis of OptiNose Correlation against competitors.
To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.29)
Revenue Per Share
0.553
Quarterly Revenue Growth
0.031
Return On Assets
(0.10)
Return On Equity
(10.51)
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.